induced-pluripotent-stem-cells, page-3

Regenerative Medicine Crossroad in Tokyo #2 on Oct. 11, 2016

1 Organization Name of Organization / 会社名 Cynata Therapeutics Ltd URL www.cynata.com Brief Descriptions of Organization / 会社概要 Cynata Therapeutics is an Australian regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, from the University of WisconsinMadison, a world leader in stem cell research. Cymerus™ addresses a critical shortcoming in existing methods of production of allogenic mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) as the starting material for allogenic MSC production. Cymerus™ provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use. This has the potential to create a new standard in the emergent arena of stem cell therapeutics. Oral Presentation Title of Presentation / 講演タイトル “Cymerus™: Scalable Production of Allogenic, iPSC-derived Mesenchymal Stem Cells (MSCs) for Therapeutic Use” Abstract / 要旨 Mesenchymal stem (or stromal) cells (MSCs) are multipotent cells, found in a range of tissues. There has been enormous interest in the therapeutic potential of MSCs, especially given that they can be used in an ‘off the shelf’, allogeneic manner, without matching the donor to the recipient. The ClinicalTrials.gov website indicates there are over 600 open clinical trials involving MSC-like products in an extremely wide range of indications. All MSC products tested in clinical trials to date have been isolated from human tissue – most commonly bone marrow. The reliance on this source has significant limitations for largescale production, with two fundamental problems: the number of MSCs that can be recovered from a tissue donation is relatively small and there is a limit to the culture expansion capacity of MSCs. Cynata’s Cymerus™ technology uses iPSCs to overcome the rate-limiting challenges facing the commercial development of allogeneic MSC therapeutic products. Objectives and/or Motives / 目的

The objective is to inform the audience about a new generation process for manufacturing therapeutic MSCs that does not rely upon multiple donors or massive expansion in culture of the MSCs. It will demonstrate a unique new technology for the utilization of the enormous potential of induced pluripotent stem cells (iPSCs